Company intelligence / Profile preview

New Medical Enzymes

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

New Medical Enzymes (NME) was a Swiss biotechnology company focused on the development of recombinant enzymes for therapeutic use. The company's primary focus was on developing improved versions of urate oxidase for the treatment of hyperuricemia and gout, aiming to reduce immunogenicity and improve half-life compared to existing treatments. Despite early development efforts, the company ceased operations and is no longer active in the biotechnology sector.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Recombinant proteinBiologicEnzyme replacement therapy
Industry: Biotech

Beyond the preview

Go deeper on New Medical Enzymes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Medical Enzymes.

Explore the full profile